In an analysis of 82 infants in the clinical trial Blake led to Blake approval , 40 percent of babies on the drug reached milestones such as sitting , crawling and walking .None of the babies that received a placebo did .The F. D. A. approved the drug months ahead of time and , because the drug treats a rare pediatric disease , granted Biogen a special voucher that it can use to gain priority the drug a future drug that would not otherwise qualify for the program .The the drug treats